找回密碼
 To register

QQ登錄

只需一步，快速開(kāi)始

掃一掃，訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: New Drug Development; An Introduction to C J. Rick Turner Book 2010Latest edition Springer Science+Business Media, LLC 2010 Clinical.Develo

[復(fù)制鏈接]
查看: 48166|回復(fù): 59
樓主
發(fā)表于 2025-3-21 17:15:59 | 只看該作者 |倒序?yàn)g覽 |閱讀模式
書(shū)目名稱New Drug Development
副標(biāo)題An Introduction to C
編輯J. Rick Turner
視頻videohttp://file.papertrans.cn/666/665160/665160.mp4
概述Discuss the latest developments in the realm of drug safety, and expands its coverage of clinical trials considerably Provides a conceptual introduction to statistics and illustrates its important rol
圖書(shū)封面Titlebook: New Drug Development; An Introduction to C J. Rick Turner Book 2010Latest edition Springer Science+Business Media, LLC 2010 Clinical.Develo
描述New Drug Development: Second Edition provides an overview of the design concepts and statistical practices involved in therapeutic drug development. This wide spectrum of activities begins with identifying a potentially useful drug candidate that can perhaps be used in the treatment or prevention of a condition of clinical concern, and ends with marketing approval being granted by one or more regulatory agencies. In between, it includes drug molecule optimization, nonclinical and clinical evaluations of the drug’s safety and efficacy profiles, and manufacturing considerations. The more inclusive term lifecycle drug development can be used to encompass the postmarketing surveillance that is conducted all the time that a drug is on the market and being prescribed to patients with the relevant clinical condition. Information gathered during this time can be used to modify the drug (for example, dose prescribed, formulation, and mode of administration) in terms of its safety and its effectiveness. The central focus of the first edition of this book is captured by its subtitle, ‘Design, Methodology, and Analysis‘. Optimum quality study design and experimental research methodology must b
出版日期Book 2010Latest edition
關(guān)鍵詞Clinical; Development; Drug; Introduction; Trial; Turner; methodology
版次2
doihttps://doi.org/10.1007/978-1-4419-6418-2
isbn_softcover978-1-4939-0091-6
isbn_ebook978-1-4419-6418-2
copyrightSpringer Science+Business Media, LLC 2010
The information of publication is updating

書(shū)目名稱New Drug Development影響因子(影響力)




書(shū)目名稱New Drug Development影響因子(影響力)學(xué)科排名




書(shū)目名稱New Drug Development網(wǎng)絡(luò)公開(kāi)度




書(shū)目名稱New Drug Development網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書(shū)目名稱New Drug Development被引頻次




書(shū)目名稱New Drug Development被引頻次學(xué)科排名




書(shū)目名稱New Drug Development年度引用




書(shū)目名稱New Drug Development年度引用學(xué)科排名




書(shū)目名稱New Drug Development讀者反饋




書(shū)目名稱New Drug Development讀者反饋學(xué)科排名




單選投票, 共有 0 人參與投票
 

0票 0%

Perfect with Aesthetics
 

0票 0%

Better Implies Difficulty
 

0票 0%

Good and Satisfactory
 

0票 0%

Adverse Performance
 

0票 0%

Disdainful Garbage
您所在的用戶組沒(méi)有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 20:22:50 | 只看該作者
板凳
發(fā)表于 2025-3-22 01:57:09 | 只看該作者
New Drug Development,novel chemical compound, i.e., a new chemical entity (NCE) or new molecular entity (NME), as its active ingredient. In the case of biologicals, attention focuses on proteins that are produced via the large-scale cultivation of microbial or mammalian cells.
地板
發(fā)表于 2025-3-22 06:21:09 | 只看該作者
5#
發(fā)表于 2025-3-22 08:52:53 | 只看該作者
Sample Size Estimation, an understanding of important concepts, including statistical significance and clinical significance, before reading about sample size estimation. Addressing sample size estimation at this point also allows a whole (short) chapter to be dedicated to this topic, thereby acknowledging its importance in clinical research.
6#
發(fā)表于 2025-3-22 14:46:51 | 只看該作者
Cardiac and Cardiovascular Safety Assessments,ng). In this chapter discussions focus on analogous evaluations in humans if a sponsor decides to move the drug molecule into clinical trials. At this point, the term investigational drug can be adopted.
7#
發(fā)表于 2025-3-22 19:43:04 | 只看該作者
8#
發(fā)表于 2025-3-22 23:20:37 | 只看該作者
9#
發(fā)表于 2025-3-23 05:19:21 | 只看該作者
General Safety Assessments,cussions of safety now move to safety assessments in clinical trials. This chapter discusses general safety assessments, and Chapter 14 addresses specialized cardiac and cardiovascular safety assessments that have recently become critical components of new drug development. Postmarketing surveillance is discussed later in Chapter 16.
10#
發(fā)表于 2025-3-23 07:34:32 | 只看該作者
Manufacturing Small Molecule Drugs and Biologicals,l. Successfully producing the drug candidate for nonclinical testing and clinical trials and manufacturing the drug for postapproval marketing are critical. Moreover, their complexity and difficulty should not be underestimated.
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-11 18:10
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
眉山市| 高陵县| 临潭县| 赣州市| 阿瓦提县| 眉山市| 株洲县| 闵行区| 益阳市| 扶风县| 蒲江县| 峨山| 灵丘县| 中方县| 防城港市| 玛曲县| 长垣县| 乾安县| 彭水| 静宁县| 咸丰县| 嫩江县| 博野县| 平乐县| 黑山县| 镇雄县| 霍邱县| 东乡| 巩义市| 大港区| 中江县| 阜城县| 内黄县| 新丰县| 天津市| 金门县| 巫溪县| 蓝田县| 久治县| 宁蒗| 莎车县|